Acute impact of the early application of alirocumab on lipoprotein (a) and interleukin-6 in patients with unstable angina pectoris: a retrospective before-after study

Author:

Xu Zhen Yu1ORCID,Zhang Lu Lu2,Wang Sheng Huang1,Wang Yong1ORCID

Affiliation:

1. Ningbo City First Hospital

2. Fudan University

Abstract

AbstractBackgroundLipoprotein (a) is a determined causal risk factor for residual risks of recurrent ischemic cardiovascular events. Alirocumab has been found to reduce lipoprotein (a) levels. However, its effects on lipoprotein (a) and inflammation marker in a Chinese population with unstable angina remain to be characterized.AimWe aimed to assess the effect of alirocumab on lipoprotein (a) and inflammatory marker in Chinese subjects with unstable angina.MethodIn aretrospective before-after study, lipoprotein (a), interleukin-6 and other lipid profiles were measured before and after 4 weeks of alirocumab treatment in 53 patients with unstable angina (UA) who had already received oral lipid-lowering therapies.ResultsThe alirocumab significantly lowered the levels of lipoprotein (a) (−11.28 mg/dL;p< 0.001) and interleukin-6 (-1.65 pg/mL;p< 0.001) after treatment. Moreover, there was a positive linear correlation between lipoprotein (a) and interleukin-6 at baseline (R=0.86;p< 0.001). Furthermore, in 11 patients with lipoprotein (a) levels ≥ 50 mg/dL at baseline, lipoprotein (a) (-27.37 mg/dL;p< 0.001) and interleukin-6 (-2.97 pg/mL;p< 0.001) decreased after treatment. In 42 patients with lipoprotein (a) levels < 50 mg/dL at baseline, lipoprotein (a) (-7.07 mg/dL;p= 0.001) and interleukin-6 (-1.31pg/mL,p< 0.001) also decreased after treatment.ConclusionsEarly application of alirocumab may be effective in reducing the levels of lipoprotein (a) and interleukin-6 in Chinese patients with unstable angina in the short term, especially in patients with lipoprotein (a) ≥ 50 mg/dL.

Publisher

Research Square Platform LLC

Reference52 articles.

1. Lipoprotein(a) and Cardiovascular Disease;Kamstrup PR;Clin Chem,2021

2. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation;Hoogeveen RC;Clin Chem,2021

3. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank;Patel AP;Arterioscler Thromb Vasc Biol,2021

4. Enigmatic role of lipoprotein(a) in cardiovascular disease;Anuurad E;Clin Transl Sci,2010

5. Relation of Plasma Lipoprotein(a) to Subclinical Coronary Plaque Volumes, Three-Vessel and Left Main Coronary Disease, and Severe Coronary Stenoses in Apparently Healthy African-Americans With a Family History of Early-Onset Coronary Artery Disease;Kral BG;Am J Cardiol,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3